van Lunzen J, Stavrou D, Reinhold S, Zanella F, Racz P, Gottesleben A, Kern P: Klinische Diagnose und neuropathologischer Untersuchungsbefund bei 20 AIDS Patienten. Med. Klinik 1992; 87: 454-459
Schmitz J, Petrasch S, van Lunzen J, Racz P, Kleine HD, Hufert FT, Kern P, Schmitz H, Tenner-Racz K: Optimizing follicular cell isolation by discontinous gradient centrifugation and use of the magnetic cell sorter (MACS). J. Immunol. Meth. 1993; 159: 189-196
van Lunzen J, Kern P, Schmitz J, Brzoska J, Flessenkämper S, Dietrich M: Short term treatmen of visceral leishmaniasis of the old world with low dose interferon gamma and pentavalent antimony. Infection 1993; 21: 362-366
Schmitz J, van Lunzen J, Tenner-Racz K, Großschupff G, Racz P, Schmitz H, Dietrich M, Hufert FT: Follicular dendritic cells (FDC) are not productively infected with HIV-1 in vivo. Adv. Exp. Med. Biol. 1994; 355: 165-168
Zhang YM, Noronha R, Bachmann S, Hemmer Ch, van Lunzen J, von Stemmen A, Kern P, Dietrich M, Ziegler R, Waldherr R, Nawroth PP: Vascular origin of Kaposi`s sarcoma: Expression of leukocyte adhesion molecule-1, thrombomodulin and tissue factor. Am. J. Pathol. 1994; 144: 51-59
Schmitz J, van Lunzen J, Tenner-Racz K, Großschupff G, Racz P, Schmitz H, Dietrich M, Hufert FT: Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. J. Immunol. 1994; 153: 1352-1359
van Lunzen J, Schmitz J, Dengler K, Schmidt L, Schmitz H, Dietrich M: Recovery of T-lymphocytes for adoptive immunotherapy by lymphapheresis of HIV-infected patients without alterations of virological, immunological or clinical parameters. Br. J. Haematol. 1994; 88: 46-51
van Lunzen J, Mertenskötter T: Therapy of disseminated Mycobacterium avium complex infection in HIV-infected patients. AIFO 1995; 10: 373-379
Pedersen C, Barton SE, Chiesi A, Skinhoj P, Katlama C, Johnson A, van Lunzen J, Hirschel B, Maayan S, Lundgren JD: HIV-related non-Hodgkin`s lymphoma among European AIDS patients. Eur. J. Haematol. 1995; 55: 245-250
Schmitz J, Petrasch S, Mews I, van Lunzen J, Kluxen B, Wurzner R, Schmitz H, Racz P: Expression of complement regulating proteins on FDC. Adv. Exp. Med. Biol. 1995; 378: 293-295
van Lunzen J, Schmitz J, Dengler K, Kuhlmann C, Schmitz H, Dietrich M: Investigations on autologous T cells for adoptive immunotherapy of AIDS. Adv. Exp. Med. Biol. 1995; 374: 57-70
Stellbrink HJ, Zöllner B, Fenner T, Lichtenberg G, van Lunzen J, Albrecht H, Thiele HG, Greten H: Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. AIDS 1996; 10: 849-857
Schreiber M, Wachsmuth C, Müller H, Hagen C, Schmitz H, van Lunzen J: Loss of antibody reactivity directed against the V3 domain of certain HIV-1 variants during disease progression. J. Gen. Virol. 1996; 77: 2403-2414
Albrecht H, Sobottka I, Emminger C, Jablonowski H, Just G, Stoehr A, Kubin T, Salzberger B, Lutz T, van Lunzen J: Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for leishmania donovani. Arch. Path. Lab. Med. 1996; 120: 189-198
Albrecht H, Sobottka I, Stellbrink HJ, van Lunzen J, Greten H: Diagnosis of disseminated toxoplasmosis using a peripheral blood smear. AIDS 1996; 10: 799-800
Sobottka I, Albrecht H, Mack D, Stellbrink HJ, van Lunzen J, Tintelnot K, Laufs R: Systemic Penicillium marneffei infection in a German AIDS patient. Eur. J. Clin. Microbiol. Infect. Dis. 1996; 15: 256-9
van Lunzen J, Tannich E, Burchard GD: Amöbenruhr und Amöbenleberabzeß. Dt. Ärztebl. 1996; 93: 3410-6
Bongarts A, von Laer D., Vogelberg Ch, Ebert K, van Lunzen J, Garweg J, Vaith P, Hufert FT, Haller O, Meyer-König U: Glycoprotein B genotype of human cytomegalovirus: distribution in HIV-infected patients. Scand. J. Infect. Dis. 1996; 28: 447-449
Bertram S, Hufert FT, van Lunzen J, von Laer D: Coinfection of individual leukocytes with human cytomegalovirus and human immunedeficiency virus is a rare event in vivo. J. Med. Virol. 1996; 50: 31-34
Hufert FT, van Lunzen J, Janossy G, Bertram S, Schmitz J, Haller O, Racz P, von Laer D: Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS 1997; 11: 849-857
Stellbrink HJ, van Lunzen J, Hufert FT, Fröschle G, Wolf-Vorbeck G, Zöllner B, Albrecht H, Greten H, Racz P, Tenner-Racz K: Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph node CD4+ T cells. AIDS 1997; 11: 1103-1110
Laue T, Mertenskötter T, Grewing T, Degen O, van Lunzen J, Dietrich M, Schmitz H: Clinical significance of qualitative human cytomegalovirus (HCMV) detection in cell-free serum samples in HIV-infected patients at risk for HCMV disease. AIDS 1997; 11: 1195-1196
Stellbrink HJ, Eggers C, van Lunzen J, Albrecht H, Greten H: Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997; 11: 1655-1657 (5,050)
van Lunzen J: Immunpathogenese der HIV-Infektion. Münch. Med. Wschr. 1997; 139: 12-14
Weiß R, Huhn D, Mitrou P, Nerl C, Schürmann D, Scheidegger C, Knauf W, Trenn G, Kronawitter U, van Lunzen J, Arasteh K, Herbst H: HIV-related Non-Hodgkin`s Lymphoma: CHOP Induction therapy and Interferon-alpha-2b/Zidovudine maintenance therapy. Leukemia and Lymphoma 1998; 29: 103-118 (1,046)
Degen O, Stellbrink HJ, Lauer J, van Lunzen J: Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells. AIDS 1998; 12: 1101-1102
Tenner-Racz K, Stellbrink HJ, van Lunzen J, Schneider C, Jacobs JP, Raschdorff B, Großschupff G, Steinman RM, Racz P: The unenlarged lymph nodes of HIV-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J. Exp. Med. 1998; 187: 949-959
Stellbrink HJ, Hufert FT, Tenner-Racz K, Lauer J, Schneider C, Albrecht H, Racz P, van Lunzen J: Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2. Antiviral Therapy 1998; 3: 209-214
van Lunzen J, Ruiz L, Arno A, Stellbrink HJ, Schneider C, Rull M, Castella E, Ojanguren I, Richman DD, Clotet B, Tenner-Racz K, Racz P: Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13: F1-F8
Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD: Disease progression in patients with HIV-1 infection. Relationship with antiretroviral treatment and increasing CD4 lymphocyte counts. Ann. Int. Med. 1999; 130(7): 570-577
Eggers C, van Lunzen J, Buhk T, Stellbrink HJ: HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid. J. Acq. Imm. Def. Syndr. Hum. Retr. 1999; 20: 259-264
Zhang L, Lewin SR, Markowitz M, Hsi-Hsun L, Skulsky E, Karanicolas R, Yuxian H, Xia J, Tuttleton S, Vesanen M, Spiegel H, Kost R, van Lunzen J, Stellbrink HJ, Wolinsky S, Borkowsky W, Paulumbo P, Kostrikis LG, Ho DD: Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J. Exp. Med. 1999; 190: 725-732
Plettenberg A, Lorenzen T, Stoehr A, Adam A, Weitner L, Hoffmann C, Carstensen C, Tsialsudis B, Chorselski G, Meyer-Thompson HG, van Lunzen J, Meyer A, Aries SP, Peters M, Fenske S, Sudeck H, Schmidt R: Aktueller Stand der antiretroviralen Therapie bei HIV-infizierten drogenaghängigen Patienten im Großraum Hamburg. Hamburger Ärzteblatt 1999, 5: 214-216
Blaxhult A, Mocroft A, Philips A, van Lunzen J, Bentwich Z, Stergiou G, Colebunders R, Benfield T, Mulcahy F, Lundgren J: Does European or non-European origin influence health care and prognosis for HIV-patients in Europe? HIV Medicine 1999; 1: 2-9
Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B: Predictors of virological success and ensuring failure among HIV+ patients starting HAART in Europe. Results from the EuroSIDA study. Archives of Internal Medicine 2000; 160: 1123-1132
Degen O, van Lunzen J, Stellbrink HJ: Early intensification of failing background antiretroviral therapy with abacavir improves viral suppression. Antiviral Therapy 2000; 5: 91-94
Eggers C, Stuerenburg HJ, Schafft T, Zoellner B, Feucht HH, Stellbrink HJ, van Lunzen J: Rapid clearance of HIV-1 from ventricular cerebrospinal fluid during antiretroviral therapy. Ann Neurol 2000, 47: 816-819
Van Vaerenbergh K, van Laethem K, Albert J, Boucher CAB, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ, Stuyver L, van Lunzen J, van Remoortel B, van Wijngaerden E, Vella S, Witvrouw M, Yerly S, de Clercq E, Desmyter J, Vandamme AM: Prevelance and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues. Antimicr Agents Chemother 2000; 44: 2109-2117
Stellbrink HJ, van Lunzen J: Lymph nodes during antiretroviral therapy. Curr Opin Infect Dis 2001; 14: 17-22
Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren J: The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. AIDS 2001; 15: 201-209
Lange CG, Stellbrink HJ, van Lunzen J: Indikationen zur Therapie der HIV-Infektion. Dt Ärztebl 2002, Februar
Degen O, van Lunzen J, Horstkotte MA, Sobottka I, Stellbrink HJ. Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis. AIDS 2002 Jul 5;16(10):1433-4
van Lunzen J, Altfeld M, Frahm N, Xu G Yu, Schneider C, Eldridge RL, Feeney ME, Meyer-Olson D, Stellbrink HJ, Walker BD: Expansion of pre-existing, lymph node-localized CD8+ T cell during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest 2002; 109: 837-843
de Weerth A, Gocht A, Seewald S, Brand B, van Lunzen J, Seitz U, Thonke F, Fritscher-Ravens A, Soehendra N: Duodenal nodular lymphoid hyperplasia caused by giardiasis infection in a patient who is immunodeficient. Gastrointest Endosc 2002 Apr; 55(4): 605-607
Stellbrink HJ, van Lunzen J, Westby M, O’Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries SP, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P: Virological and Immunological Effects of Highly Active Anti-Retroviral Therapy (HAART) Combined with Interleukin-2 in the Treatment of Asymptomatic HIV-1 Infection - Results of a randomized trial (COSMIC). AIDS 2002 Jul 26; 16(11): 1479-1487
Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003 Sep 5;17(13):1897-906
Lichterfeld M, Nischalke HD, van Lunzen J, Söhne J, Schmeisser N, Woitas R, Sauerbruch T, Rockstroh JK, Spengler U: The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the suscebtibility to HIV infection and progression to AIDS. Clinical Immunology 2003; 107: 55-59
Hess C, Altfeld M, Thomas S, Addo M, Rosenberg ES, Stellbrink HJ, van Lunzen J, Walker BD, Luster AD: Full maturation of HIV-specific CD8 T cells is associated with control of viral replication. Lancet 2004 Mar 13;363:863-6
Hoffmann C, Chow KU, Wolf E, Faetkenhauer G, Stellbrink H-J, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth J-C, Rockstroh J, Mosthaf F, Horst H-A, Brodt H-R. Strong impact of highly active antiretroviral therapy on survival in patients with HIV-associated Hodgkin's disease. Br J Haematol 2004;125(4):455-62
Banki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, Falkensammer B, Stellbrink HJ, van Lunzen J, Trkola A, Dierich MP, Stoiber H. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 2005 Mar 25;19(5):481-6
Steininger C, van Lunzen J, Tintelnot K, Sobottka I, Rohde H, Horstkotte MA, Stellbrink HJ: Mycotic Brain Abscess Caused by Opportunistic Reptile Pathogen. Emerging Infectious Diseases 2005 Feb;11(2):349-50
Mocroft A, Oncea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren J. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 2005 Jul; 100(7):1446-54
Popovic M, Tenner-Rácz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, Kalyanaraman V, Gallo RC, Rácz P: Persistence of HIV-1 Structural Proteins and Glycoproteins in Lymph Nodes of Patients under HAART. PNAS 2005 Oct 11; 102(41):14807-12
Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, Stahmer I, van Lunzen J, Lichterfeld M, Gao X, Allen TA, Carrington M, Walker BD, Rockstroh J and Altfeld M: Immunological and Virological Impact of HAART during acute HIV-1 infection. J Infect Dis. 2006 Sep 15;194(6):734-9
Banki Z, Wilflingseder D, Ammann CG, Pruenster M, Muellauer B, Hollaender K, Meyer M, Sprinzl GM, van Lunzen J, Stellbrink HJ, Dierich MP, and Stoiber H: Factor I-Mediated Processing of Complement Fragments on HIV Immune Complexes Targets HIV to CR2-Expressing B Cells and Facilitates B Cell-Mediated Transmission of Opsonized HIV to T Cells. J Immunol. 2006 Sep 1;177(5):3469-76
von Laer D, Baum C, Schambach A, Kuehlcke K, Zahn R, Newrzela S, van Lunzen J, Johnson RP, Schmitz J: Gene Therapy Approaches for AIDS. CMC 2006 (in print)
Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA.: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006 Sep;47(9):1872-80
van Lunzen J, Hoffmann C: Virological rebound and its consequences during treatment interruption. Curr Opin HIV & AIDS 2006 (in print)
Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, Wolf E, van Lunzen J: Adoptive Transfer of Sygenic T Cells in HIV-1 Discordant Twins Indicates Rapid Regulation of T-Cell Homeostasis. Br J Haematol. 2007 Jan 11
van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, Müller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D: Transfer of Autologous Gene-Modified T Lyymphocytes in HIV-infected Patients with Advanced Immunodeficiency and Multidrug Resistant Viruses. Mol Therapy 2007 (in print)
van Lunzen J, Liess H, Arasteh K, Walli R, Daut B, Schürmann D: Concomitant use of gasric acid-reducing agents is frequent among HIV-1 infected patients receiving protease inhibitor (PI) based highly active antiretroviral therapy (HAART). HIV Medicine 2007 (in print)
Lehmann C, Taubert D, Hartmann P, Fätkenheuer G, Kaiser R, Schömig E, Stellbrink HJ, van Lunzen J, Gallo RC, Romerio F: Increased IFN-alpha expression in peripheral blood of HIV-1 infected patients despite selective loss of plasmacytoid dendritic cells. PNAS 2007 (in print)
Meier A, Alter G, Frahm N, Sidhu H, Li B, Teigen N, Streeck H, Stellbrink HJ, van Lunzen J, Altfeld M: HIV-1 encodes for multiple uridine-rich ssRNA oligonucleotides with strong immune-stimulatory activity. (submitted)
Salzberger B, Däumer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Stürmer M: Consensus recommendation from a group of German experts for the use of enfurvitide in heavily pretreated HIV patients. (submitted)
